

Orahn Preiss-Bloom is a seasoned entrepreneur and executive with a track record of building innovative companies in the healthcare sector. As the Founder and Chief Innovation Officer of OSSIO Ltd., he pioneered OSSIOfiber®, a unique biointegrative implant technology that combines the strength of orthopedic fixation implants with the ability to integrate naturally into the body over time. Together with a veteran executive leadership team, he has helped drive widespread commercial adoption of OSSIOfiber® implants, making OSSIO one of the fastest growing companies in the fields of orthopedic sports medicine and distal extremities. Previously, Preiss-Bloom was Co-founder and Chief Technology Officer at LifeBond®, a biosurgery company focused on advanced soft tissue repair, where he helped grow the company from concept phase through regulatory approval and initial revenues. LifeBond® was acquired in 2019 by CR Bard® Inc, now part of BD (NYSE: BDX). Preiss-Bloom holds a BSc (Columbia University) and MSc (Technion) in Biomedical Engineering and has conducted translational medical research at Columbia University's Department of Orthopedic Surgery. In his role at OSSIO®, he is able to leverage his ability to merge cutting-edge technology with clinical needs to create transformative products in the orthopedic industry.